Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GRAM domain-containing protein 4 (GRAMD4)
- Target
- GRAMD4
- Molecular classification
- Membrane-associated protein (via its GRAM domain and transmembrane regions), Adaptor protein (induces cell death signaling, interacts with apoptosis proteins), Other: Apoptosis mediator
01
Overview
GRAM domain-containing protein 4 (GRAMD4) is a mitochondrial adaptor protein that mediates apoptosis independently of p53, primarily under regulation by the transcription factor p73. Following cellular stress or DNA damage (e.g., chemotherapeutic agent cisplatin), p73 activates GRAMD4 transcription. GRAMD4 then translocates to mitochondria, interacts with the anti-apoptotic protein Bcl-2, and promotes the activation and oligomerization of Bax, leading to mitochondrial membrane permeabilization, cytochrome c/Smac release, and caspase-3 activation. The protein contains a GRAM domain, two transmembrane domains, and a Bcl-like region facilitating protein-protein interactions in the apoptotic cascade. It is implicated in the execution phase of programmed cell death and has potential relevance in cancer therapy and biomarker development
- Other names
- Death-inducing protein (DIP)KIAA0767dA59H18.1dJ439F8.1GRAMD4DIPGRAM domain containing 4
02
Mechanism of action
Drugs like cisplatin upregulate p73, which directly transactivates GRAMD4. GRAMD4 translocates from nucleus to mitochondria, binds Bcl-2, releases apoptotic factors (cytochrome c, Smac), and induces caspase-3 activation
03
Biological functions
Apoptosis induction (especially as a p73-dependent mediator)Cell death regulationMitochondrial membrane permeabilization (by interacting with Bcl-2 and Bax)Immune response modulation (inhibition of TLR9 response)
04
Disease associations
Cancer (notably in lung squamous cell carcinoma; involved in chemotherapy-mediated tumor cell killing)Potential roles in other diseases via apoptosis and chromosome 15Q11.2 deletion syndrome
05
Safety considerations
Excess apoptosis may lead to tissue degeneration. Therapeutic targeting would require careful modulation to avoid off-target cytotoxicity, particularly in non-cancer cells
06
Interacting drugs
Cisplatin (induces GRAMD4 transcription in response to DNA damage)
07
Biomarkers
GRAMD4 expression level may serve as a biomarker for p73-dependent apoptosis and for response to DNA-damaging chemotherapy
Beyond the preview
Go deeper on GRAM domain-containing protein 4 (GRAMD4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRAM domain-containing protein 4 (GRAMD4).